Anti-platelet and anti-hypertension medication use in patients with fibromuscular dysplasia: Results from the United States Registry for Fibromuscular Dysplasia

In conclusion, in FMD, medication use varies based on vascular bed involvement. Isolated renal FMD patients receive more anti-HTN agents and there is greater anti-platelet agent use among patients with cerebrovascular FMD. Further studies correlating medication use in FMD with clinically meaningful patient outcomes are necessary.

Source: Vascular Medicine - October 2, 2015 Category: Internal Medicine Authors: Weinberg, I., Gu, X., Giri, J., Kim, S. E., Bacharach, M. J., Gray, B. H., Katzen, B. T., Matsumoto, A. H., Chi, Y.-W., Rogers, K. R., Froehlich, J., Olin, J. W., Gornik, H. L., Jaff, M. R. Tags: Original Articles Source Type: research